Krystal Biotech
KRYS
160 hedge funds and large institutions have $1.68B invested in Krystal Biotech in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 56 increasing their positions, 55 reducing their positions, and 11 closing their positions.
82% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 11
5% more funds holding
Funds holding: 153 → 160 (+7)
1.77% more ownership
Funds ownership: 79.67% → 81.44% (+1.8%)
3% more capital invested
Capital invested by funds: $1.62B → $1.68B (+$54.2M)
2% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 55
9% less call options, than puts
Call options by funds: $10.6M | Put options by funds: $11.7M
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$26.7M |
| 2 |
DM
Deerfield Management
New York
|
+$10.8M |
| 3 |
Goldman Sachs
New York
|
+$8.66M |
| 4 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$8.46M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$7.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$24.9M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$21.8M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$9.99M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$8.09M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$7.34M |
KRYS Hedge Fund Activity: Q1 2023 in Review
160 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q1 2023, worth a combined $1.68B — up 3.3% from $1.62B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new KRYS positions and 11 closed out — a net gain of 9 holders — while 56 added to existing stakes and 55 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $26.7M. The largest seller was Lord, Abbett & Co, cutting an estimated $24.9M.
- 160 institutional investors held Krystal Biotech (KRYS) as of Q1 2023, up from 153 in Q4 2022.
- Funds reported $1.68B of Krystal Biotech stock for Q1 2023, up 3.3% quarter-over-quarter.
- 20 funds opened new Krystal Biotech positions in Q1 2023 and 11 closed out, a net change of +9 holders.
- The largest Krystal Biotech buyer in Q1 2023 was Avoro Capital Advisors, an estimated $26.7M added.
- The largest Krystal Biotech seller in Q1 2023 was Lord, Abbett & Co, an estimated $24.9M sold.
Based on aggregated 13F filings for Q1 2023.